NJ-TRANE-TECHNOLOGIES
30.8.2021 12:47:05 CEST | Business Wire | Press release
Thermo King , a brand of global climate innovator Trane Technologies (NYSE: TT), today announced that it will invest more than $100 million over the next three years to deliver a fully electric product in every segment of the cold chain by 2023.
The company’s all-electric portfolio, branded evolve™, will include electric refrigeration solutions for truck, trailer, rail, air and marine transport in the North America, Latin America and Europe, Middle East and Africa (EMEA) regions. The evolve portfolio aligns with customers’ goals to transition to more sustainable solutions for their fleets, and will help advance Trane Technologies’ 2030 Sustainability Commitments , including its Gigaton Challenge to reduce customer greenhouse gas emissions by 1 billion metric tons.
As new products are added to the evolve portfolio, electric solutions will be available in every cold chain segment in EMEA by 2023, and in the Americas by 2025.
“Bold solutions for a more sustainable world are core to our strategy. We continue to innovate to help reduce the carbon footprint of customer operations,” said Paul Camuti, chief technology and sustainability officer for Trane Technologies. “The evolve portfolio builds on our ongoing efforts to help customers reduce environmental impact and meet their sustainability goals as they transition fleets and stay ahead of future regulation.”
The global leader in temperature control solutions already offers fully electric products such as the E-200 for middle and last-mile delivery, and the TE-18 and Athenia™ all-electric HVAC units for public bus transit. Successfully launched in EMEA in 2020, the Advancer trailer unit is 30% more fuel efficient than the market average and can operate on a variety of power sources such as shore power, hybrid, holdover battery and axle generator. In the Americas region, the enhanced electric architecture on the connected Precedent™ trailer unit leverages shore power and will undergo field trials with customers later this year. These innovations will pave the way for all-electric zero-emission trailer refrigeration units in both regions.
“Our expertise in electrification has positioned Thermo King as a trusted partner to respected industry leaders such as Isuzu, Tesco, Mercedes-Benz and technology companies such as ELMS, Gatik and BPW who continue to find new ways to innovate the cold chain,” said Karin De Bondt, president for Thermo King Americas. “Through these strategic partnerships we are able to further our advancements of sustainable power solutions and electrified product offerings that meet customer, regulatory and environmental requirements in our industry and our world.”
Providing electric solutions for buildings, homes and refrigerated transportation is part of Trane Technologies’ overall approach to reducing carbon emissions in the industries it serves, meeting its Gigaton Challenge for a more sustainable future, and supporting net-zero cities.
*The Thermo King evolve™ portfolio will include fully electric products and hybrid products using an internal combustion engine for an emergency backup power source only.
About Thermo King
Thermo King – by Trane Technologies (NYSE: TT), a global climate innovator – is a worldwide leader in sustainable transport temperature control solutions. Thermo King has been providing transport temperature control solutions for a variety of applications, including trailers, truck bodies, buses, air, shipboard containers, and railway cars since 1938. For more information, visit www.thermoking.com or www.europe.thermoking.com .
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane and Thermo King, and our environmentally responsible portfolio of products and services, we bring efficient and sustainable climate solutions to buildings, homes, and transportation. Learn more at tranetechologies.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005123/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom